RECRUITING

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Description

This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

Conditions

Metastatic Lobular Breast Carcinoma
Talk to us

Related Conditions:

Metastatic Lobular Breast Carcinoma

Study Overview

On this page

Study Details

Study overview

This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)

Condition
Metastatic Lobular Breast Carcinoma
Intervention / Treatment

-

Contacts and Locations

Sacramento

University of California Davis, Sacramento, California, United States, 95817

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * (Ability to understand and willingness to sign a written informed consent document.
  • * Men and women age ≥ 18 yrs
  • * Confirmed presence of metastatic/advanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1)
  • * Available archival tumor tissue
  • * Eastern Cooperative Oncology Group Performance Status ≤ 2
  • * Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells/mm3,Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL.
  • * Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, creatinine clearance \>60 mL/min.
  • * Anticipated life expectancy ≥ 3 months
  • * Able to remain motionless for up to 30-60 minutes per scan.
  • * Pregnant and lactating women
  • * Prisoners
  • * Concurrent malignancy of a different histology that could confound imaging interpretation.
  • * Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)

Ages Eligible for Study

18 Years to 89 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Davis,

Julie Sutcliffe, PhD, PRINCIPAL_INVESTIGATOR, University of California, Davis

Study Record Dates

2027-06